Abstract:To the Editor: A 74-year-old man was admitted to the First-Aid department because of persistent fever (391C), vomiting, and mucous-hemorrhagic diarrhea. The patient had no remarkable recent medical history except for hepatitis C infection. He was a pensioner, lived alone in Western Sicily (Italy), had no pets and frequently ate homemade foods as fresh and frozen meat (beef and pork steaks, chickens). Physical examination was normal except for a right subcostal painless or slightly tender hepatomegaly. Leukocyte count and serodiagnosis (Vidal-Wright) were normal. Ultrasound examination of the abdomen revealed a suspect hepatic abscess (2 3 cm) in the VII hepatic segment. Electrocardiography and chest radiography were normal. Empiric intravenous chemotherapy with piperacillin plus tazobactam (4g plus 0.500 g twice/day) was initiated. The following day the patient was still febrile (391C) and started derangement and delirium and slight stiff neck. Prednisolone (2mg/kg) and a dose of intravenous immunoglobulin (2 g/kg) were administered. On day 3 the patient was transferred to a neurologic department where acyclovir was added. Two blood cultures and lumbar puncture were negative. Over the following 3 days the patient’s condition improved slowly except for a slight clouding of consciousness and remittent fever (38, 51C to 391C). The patient was transferred to our department on day 5. He presented continuous fever (39.51C), coma (I degree), periodic apnea crisis and intermittent tremor. Neurologic examination showed paresis on the right side; deep tendon reflexes were brisk in the lower extremities and bilateral Babinski reflexes were positive. Blood and stool cultures were performed twice and antiedematous therapy was initiated. Anti-Yersinia antibody (IgA) was positive (1/800). Stool and abscesses cultures (assessed by liver puncture) were repeatedly positive for Yersinia enterocolitica infection; antibiogram was performed. PCR detected Y. enterocolitica (biotype 0:3) in blood. Contrast-enhanced computed tomodensitometric scan showed intraparenchyma areas of hypodensity consistent with cerebrocortical infarcts. Magnetic resonance imaging confirmed multiple peritrigonal and periventricular microabscesses in white matter. The patient was treated with ciprofloxacin (200mg q12h IV) for 10 days and his condition gradually improved and he was transferred to Rehabilitation Unit after 3 weeks. Y. enterocolitica as a collection of organisms is widespread in nature and terrestrial and aquatic ecosystems may become contaminated. The usual route of acquisition of Y. enterocolitica is through ingestion of food (meat, milk, etc) or water contaminated with the bacterium; as most of the contaminated food associated with outbreaks have cycled through refrigeration temperature which favors the growth of Y. enterocolitica, it must undergo a temperature adaptation in the human host before the initiation of an infection process. Y. enterocolitica withstands freezing very well and may survive for prolonged periods in frozen foods; in fact has been isolated even in frozen seafood; it shows elevated heat resistance in liquids. After ingestion, virulent plasmid-containing Y. enterocolitica attaches and invades M cells overlying Peyer patches by first binding to, and traversing, the mucus layer pathing mucosal epithelial cells. Clinically, Y. enterocolitica is primarily a gastrointestinal tract pathogen but it can induce extraintestinal spread under appropriate host (in relation to the age, immunologic status, and comorbidity). Some authors hypothesized immunologic involvement in acute and chronic neurologic disease during yersiniosis, but very little is known about possible neurologic manifestations associated with Y. enterocolitica infection. Our patient was a habitual eater of homemade foods as fresh and frozen meat. He presented a chronic Hepatitis C virus infection and this infection is associated with some immune system alterations and elevated levels of cytokine proinflammatory; has been reported that tumor necrosis factor-a, interleukin-2, and interleukin-6 can favor Yersinia infection. What remains remarkable in our case is the initial missed diagnosis of pyogenic liver and cerebral infection that led to unjustified steroid and antiviral therapy. Even though the patient’s leukocyte count and serodiagnosis were normal, the US signs of parenchimale abscesses should have initiated a thorough search for an unusual infective cause. Y. enterocolitica is primed to establish enteric tract pathology or to cause systemic disease in the appropriate host setting and physicians should consider this infection in their diagnostic proceeding and in routine testing of stool specimens.

Packaged delivery of CRISPR-Cas9 ribonucleoproteins accelerates genome editing

Septicemia, hepatic abscess, and encephalitis due to Yersinia enterocolitica.

Non-viral Delivery of CRISPR–Cas9 Complexes for Targeted Gene Editing Via a Polymer Delivery System

Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing

[Reevaluation of spinal anesthesia in elderly people--an evaluation of circulatory changes].

Mechanism-guided engineering of a minimal biological particle for genome editing

Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing

Identification of a swine influenza virus (Hsw1N1) isolated from a duck in Hong Kong.

Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.

Engineering self-deliverable ribonucleoproteins for genome editing in the brain

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Poly(Beta-Amino Ester) Nanoparticles Enable Nonviral Delivery of CRISPR-Cas9 Plasmids for Gene Knockout and Gene Deletion

Pre-procedural imaging of aortic root orientation and dimensions: comparison between X-ray angiographic planar imaging and 3-dimensional multidetector row computed tomography.

Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA

pH‐Responsive Polymer Nanoparticles for Efficient Delivery of Cas9 Ribonucleoprotein With or Without Donor DNA

CRISPRs for Optimal Targeting: Delivery of CRISPR Components as DNA, RNA, and Protein into Cultured Cells and Single-Cell Embryos

Block Polymer Micelles Enable CRISPR/Cas9 Ribonucleoprotein Delivery: Physicochemical Properties Affect Packaging Mechanisms and Gene Editing Efficiency

An Efficient Expression and Purification Protocol for SpCas9 Nuclease and Evaluation of Different Delivery Methods of Ribonucleoprotein

Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation